Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 22 ·No. 10 ·2004-05-15 ·Pages 2035-6; author reply 2036-7

Normanno N, Di Maio M, Perrone F, Campiglio M

Abstract

暂无摘要

MeSH Terms

Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Non-Small-Cell Lung/drug therapy,metabolism Confounding Factors, Epidemiologic ErbB Receptors/administration & dosage,metabolism Gefitinib Humans Lung Neoplasms/drug therapy,metabolism Quinazolines/therapeutic use

Chemicals

Antineoplastic Agents Biomarkers, Tumor Quinazolines ErbB Receptors Gefitinib

Authors & Affiliations

4 authors, click to expand affiliations / ORCID

Normanno Nicola

Di Maio Massimo

Perrone Francesco

Campiglio Manuela

Article Info

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Abbr.

J Clin Oncol

ISSN

0732-183X

DOI

10.1200/JCO.2004.99.337

Published

2004-05-15

Pages

2035-6; author reply 2036-7

Language

English

Region

United States

NLM ID

8309333

Subset

Corrections

CommentOn

PMID: 12860941

CommentIn

PMID: 15923592

External Links

PubMed source DOI: 10.1200/JCO.2004.99.337 View journal details

Analysis Services

Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?

Contact

WeChat Official Account